Compare
Nuvectis Pharma, Inc. vs Tvardi Therapeutics, Inc. vs Rein Therapeutics, Inc. vs Immunic, Inc.
| Latest fiscal year | Nuvectis Pharma, Inc. NVCT | Tvardi Therapeutics, Inc. TVRD | Rein Therapeutics, Inc. RNTX | Immunic, Inc. IMUX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $0 | n/a |
| Revenue growth (YoY) | n/a | n/a | n/a | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/a |
| Net margin | n/a | n/a | n/a | n/a |
| Net income | -$26.44M | -$18.21M | -$49.87M | -$97.17M |
| EPS (Diluted) | -$1.32 | -$3.26 | -$1.96 | -$0.62 |
| Operating cash flow | -$16.01M | -$23.50M | -$19.36M | -$85.81M |
| Free cash flow | n/a | n/a | n/a | -$85.97M |
| Cash & equivalents | $31.63M | $20.73M | $3.21M | $15.48M |
| Total assets | $31.71M | $32.07M | $24.16M | $24.05M |
| Total liabilities | $13.30M | $11.13M | $7.24M | $30.73M |
| Shareholders' equity | $18.41M | $20.95M | $16.92M | -$6.67M |
| Return on year-end equity | -143.6% | -87.0% | -294.8% | n/a |
| Shares outstanding | 25.68M | 9.38M | 27.55M | 90.15M |
Revenue, most recent five fiscal years
| Fiscal year | Nuvectis Pharma, Inc. | Tvardi Therapeutics, Inc. | Rein Therapeutics, Inc. | Immunic, Inc. |
|---|---|---|---|---|
| Latest | n/a | $7.14M Ended 2024-12-31 | $0 Ended 2025-12-31 | n/a |
| 1 year earlier | n/a | $20.97M Ended 2023-12-31 | $0 Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | $41.87M Ended 2022-12-31 | $0 Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | $23.03M Ended 2021-12-31 | $0 Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $135.08M Ended 2020-12-31 | $0 Ended 2021-12-31 | n/a |